NCT06672575View on ClinicalTrials.gov

A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

45

Participants

Timeline

Start Date

January 30, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2030

Conditions

Glioblastoma

Interventions

DRUG

Ivonescimab

Participante will recived an infusion by vein

Trial Locations (2)

77030

RECRUITING

The University of Texas M. D. Anderson Cancer Center, Houston

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Summit Therapeutics

All Listed Sponsors

collaborator

Summit Therapeutics

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER